title: [Efficacy of bFGF atomization inhalation on postoperative sore throat following oral and maxillofacial surgery under general anesthesia].
abstract: OBJECTIVE
  To observe the effect of recombinant human basic fibroblast growth factor (bFGF) atomization inhalation on postoperative sore throat following oral and maxillofacial operation under general anethesia.
  
  
  METHODS
  Forty patients in whom oral and maxillofacial operation trachea was removed under general anesthesia were randomly divided into treatment and control groups; the treatment group received bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d; the control group was given normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d. Occurrence of postoperative sore throat 12 h after operation was recorded and visual analog scale (VAS) of sore throat (swallowing) 12,24,48,72 h after operation was measured. SPSS l4.0 software package was used for statistical analysis.
  
  
  RESULTS
  The incidence of sore throat in the treatment group was significantly lower than that in the control group (P<0.01) 12 h after operation; sore throat (swallowing) VAS 12,24,48 and 72 h after operation in the treatment group were significantly lower than that in the control group (P<0.05).
  
  
  CONCLUSIONS
  bFGF atomization inhalation can reduce the incidence of sore throat and sore throat level in oral and maxillofacial surgery after endotracheal intubation.
authors.affiliation: Wenzhou Medical University. Wenzhou 355035, Zhejiang Province, China. E-mail:doctorliubin@163.com.
authors.forename: Bin
authors.initials: B
authors.lastname: Liu
authors.forename: Yin-Hua
authors.initials: YH
authors.lastname: Jiang
authors.forename: Jian
authors.initials: J
authors.lastname: Xiao
authors.forename: Xiao-Kun
authors.initials: XK
authors.lastname: Li
mesh_terms: D000768:Anesthesia, General; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D007442:Intubation, Intratracheal / Q000009:adverse effects*; D010147:Pain Measurement; D010612:Pharyngitis / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications; D011184:Postoperative Period; D011312:Pressure; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013515:Surgery, Oral
chemical_list: D000893:Anti-Inflammatory Agents; C100666:KCB-1 protein, recombinant; D011994:Recombinant Proteins; D016222:Fibroblast Growth Factor 2; D003907:Dexamethasone